CINOD

AcronymDefinition
CINODCyclooxygenase-Inhibiting Nitric Oxide Donor (pharmacology)
Copyright 1988-2018 AcronymFinder.com, All rights reserved.
References in periodicals archive ?
"CINODs, through NO release, may potentially counteract the detrimental effects of COX inhibition on blood pressure and may prove to be beneficial in patients with osteoarthritis and concomitant cardiovascular risk factors," Dr.
NicOx's reacquisition of the CINOD rights follows AstraZeneca's decision not to advance the lead product, AZD3582, into Phase III trials.
Naproxcinod, the first-in-class CINOD (Cyclooxygenase-Inhibiting Nitric Oxide-Donating) anti-inflammatory drug-candidate developed for the relief of the signs and symptoms of OA, is currently under review by the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA).
Naproxcinod is the first-in-class CINOD (Cyclooxygenase-Inhibiting Nitric Oxide-Donating) anti-inflammatory drug candidate developed for the relief of the signs and symptoms of OA, which is currently under review by regulatory authorities.
Naproxcinod is the company's first-in-class CINOD (Cyclooxygenase-Inhibiting Nitric Oxide-Donating) anti-inflammatory drug-candidate developed for the relief of the signs and symptoms of OA, which is currently under review by regulatory authorities.
Recently, the CINODs have been developed by adding a nitric-oxide-donating group to a NSAID, with early trials of naproxcinod showing good efficacy but less risk of CV and GI events.